The launch of a second Remicade biosimilar could open the floodgates to biosimilar competition in the specialty drug market.
John Bujnoski
Advertisement
Articles by John Bujnoski
Advertisement
Latest Updated Articles
Has the US Biosimilar Market Reached a Tipping Point?Published: August 8th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
4
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
5
